Curative and prophylactic therapies for microvascular and/or macrovascular thrombosis are provided, as are prophylactic therapies capable of preventing fibrinolysis shutdown and therapies for non-thrombotic disorders. Methods provide for administering a therapeutically effective amount of an annexin A2.
展开▼